BLZ945 is a potent and selective CSF-1R inhibitor which was shown to attenuate tumor growth by depleting TAMs and enriching CD8+ T cells in a murine K14-HPV-16 cervical cancer mouse model [122]. Here, CD8A is linked to neoplasm.